Skip to main content

Advertisement

Figure 9 | Molecular Cancer

Figure 9

From: High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde

Figure 9

Suppression of DNA-PKcs leads to an increase of cell surface expression of DR5. (A) PC3 and KM12 cells were transfected with siRNA against DNA-PKcs or scrambled siRNA as a control. After 48 h, the transfected cells were treated with the indicated doses of TRAIL for 2 h. Thereafter, the transfected cells were incubated with anti-DR5 antibody (1:100), and subsequently labeled with FITC-conjugated secondary antibodies (1:200) to determine the surface expression of DR5. (B) PC3 (upper) and KM12 cells (lower) were treated with 5 μM DMNB for 4 and 6 h, and then incubated with an anti-DR5 antibody (1:100), and subsequently labeled with FITC-conjugated secondary antibodies (1:200) to determine the surface expression of DR5. Mouse IgG was used as an isotype control. The shaded and unshaded peaks correspond to control and specific staining, respectively.

Back to article page